TICKERNERD
Menu
QGENQGENHealthcare · Diagnostics & Research

QGEN Stock Forecast: Qiagen NV Price Predictions for 2026-2027

Last close, 14 Aug 2026
$43
−0.65% on the day

The 15 Wall Street analysts covering Qiagen NV hold a median 12-month price target of $47 — +8.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$8.9B
Ticker Nerd rank
62 / 100
Median analyst target
$47
Analysts covering
15
Total return, dividends reinvested
1W
+1.5%
1M
+3.3%
YTD
−8.5%
1Y
−11.5%
From 52W high
−22.1%
From 52W low
+32.8%
$32
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Qiagen NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
98
Quality
77
Accruals
56
Revisions
56
Growth
49
Issuance
40
Momentum
36
Size
17

Volatility (98): The share price has been relatively steady.

Momentum (36): The shares have been drifting down relative to others.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$35$40$45$50$55Oct 25Jan 26Apr 26Jul 26QGENHigh $50Median $47Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
8 Buy7 Hold0 Sell
Low $40Median $47High $50

The green dot is the last close — the median target sits +8.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Aug 2026CitigroupMaintainsNeutral$38 → $45
7 Aug 2026BarclaysMaintainsEqual-Weight$38 → $40
7 Aug 2026JP MorganMaintainsOverweight$45 → $50
23 June 2026Morgan StanleyUpgradeOverweight$40 → $42
23 June 2026Morgan StanleyUpgradeOverweight—
18 May 2026StifelMaintainsHold—
7 May 2026TD CowenMaintainsHold—
29 Apr 2026BairdUpgradeOutperform—
29 Apr 2026BarclaysMaintainsEqual-Weight—
29 Apr 2026CitigroupMaintainsNeutral—
29 Apr 2026JP MorganMaintainsOverweight—
14 Apr 2026BarclaysDowngradeEqual-Weight—
13 Mar 2026Deutsche BankUpgradeBuy—
6 Feb 2026CitigroupMaintainsNeutral—
6 Feb 2026JP MorganMaintainsOverweight—
6 Feb 2026StifelMaintainsHold—
22 Jan 2026Deutsche BankDowngradeHold—
15 Dec 2025BarclaysMaintainsOverweight—
11 Dec 2025CitigroupDowngradeNeutral—
2 Oct 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

QGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
2
Analysts cutting
2
Fundamentals

Qiagen NV (QGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.8×

Cheaper than 36% of US stocks

Price / sales
4.2×

Cheaper than 30% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
13.3×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
0.3%

Higher than 28% of US stocks

Earnings growth (YoY)
7.4%

Higher than 45% of US stocks

Gross margin
63.6%

Higher than 77% of US stocks

Operating margin
26.3%

Higher than 85% of US stocks

Net margin
19.5%

Higher than 82% of US stocks

Returns & dividend
Return on equity
11.9%

Higher than 68% of US stocks

Return on assets
5.9%

Higher than 81% of US stocks

Dividend yield
0.8%

Higher than 18% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

QGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
QGENQiagen NV$8.9B
62
TWSTTwist Bioscience Corp.$7.8B
63
ICLRIcon PLC$12.5B
67
RVTYRevvity, Inc.$13.0B
93
RDNTRadNet, Inc.$5.9B
34
CRLCharles River Laboratories International, Inc.$13.8B
84
SHCSotera Health Co.$5.4B
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Qiagen NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QGEN news & analysis

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

Business Wire · 10 Aug 2026positive

QIAGEN announced that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. This clearance expands QIAGEN's U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform.

Why it matters — The FDA clearance adds a new infectious disease category to QIAGEN's U.S. QIAstat-Dx syndromic testing portfolio, broadening the platform's diagnostic market reach.

Understanding Qiagen (QGEN) Reliance on International Revenue

Zacks Investment Research · 10 Aug 2026neutral

Zacks Investment Research examines Qiagen's (QGEN) reliance on international revenue as a factor in assessing the company's financial stability, growth prospects, and potential stock price performance.

Why it matters — QGEN watchers would care because the company's international revenue exposure is a key determinant of its financial stability and growth outlook.

Qiagen Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Qiagen reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both reported and constant-exchange-rate bases. This outperformed the company's forecast of an approximately 2% decline at constant exchange rates.

Why it matters — A QGEN watcher would care because the company beat its own sales guidance by posting flat rather than declining revenue, indicating better-than-expected performance for the quarter.

Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published a transcript of Qiagen N.V.'s Q2 2026 earnings call, in which the company discussed its quarterly results and fielded questions from analysts.

Why it matters — A QGEN watcher would care because the transcript offers a full record of management's commentary on the company's second-quarter performance.

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Qiagen reported Q2 earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares with earnings of $0.63 per share a year earlier, and the company also beat revenue estimates, according to the headline.

Why it matters — The earnings and revenue beats show Qiagen's quarterly results came in ahead of analyst expectations, which is relevant for QGEN watchers tracking performance versus consensus.

FAQ

Frequently asked questions about QGEN stock

What is the QGEN stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Qiagen NV have a median 12-month price target of $47, with estimates ranging from $40 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QGEN stock a buy right now?

Of the 15 analysts covering Qiagen NV, 8 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Qiagen NV 62 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QGEN?

As at 15 Aug 2026, Qiagen NV ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will QGEN stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +8.3% from the last close, and Ticker Nerd's factor model ranks Qiagen NV 62 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QGEN stock forecast for 2030?

No analyst covering Qiagen NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $50 over the next 12 months.

How has QGEN stock performed over the past year?

Qiagen NV returned -11.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Qiagen NV do?

QIAGEN N.V. is a Netherlands-based holding company and the leading global provider of Sample to Insight solutions that transform biological samples into valuable molecular insights.

What is the latest news on QGEN?

The most recent item we track (Business Wire, 10 Aug 2026): "QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel". QIAGEN announced that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. This clearance expands QIAGEN's U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform.

Company

About Qiagen NV.

QIAGEN N.V. is a Netherlands-based holding company and the leading global provider of Sample to Insight solutions that transform biological samples into valuable molecular insights. Founded in Germany in 1984, it specializes in technologies for isolating and processing DNA, RNA, and proteins from blood, tissue, and other materials, alongside assay technologies, bioinformatics software, and automation workflows for analysis. The company serves over 500,000 customers worldwide across molecular diagnostics for human healthcare, applied testing in forensics, veterinary, and food safety, pharmaceutical and biotech R&D, and academic life sciences research. With more than 500 core products including disposable kits, automated workstations, and testing agents, QIAGEN operates in over 130 countries, with key locations in Venlo, Netherlands; Hilden, Germany; and regional hubs in the US, China, and Singapore. Employing thousands globally and led by CEO Thierry Bernard, QIAGEN plays a pivotal role in advancing scientific discovery, disease diagnosis, and personalized medicine through innovative molecular tools. Its extensive acquisition history, including companies like Digene, Cellestis, and Verogen, has expanded its capabilities in diagnostics and bioinformatics. QIAGEN N.V. significantly contributes to the life sciences and healthcare sectors by enabling faster, more reliable molecular analysis.

CEO Mr. Thierry L. Bernard · 5,500 employees · Netherlands · https://www.qiagen.com